Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

US Patent 11369658 · Granted Jun 28, 2022

Estimated economic value: $309,040,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2023
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2023
Combination of CD33 antibody drug conjugates with chemotherapeutic agents2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2020
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2020
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2019